Argos Therapeutics Inc fka ARGSQ

[declaes]

If the Company does not regain compliance with the Bid Price Requirement by the Bid Price Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to transfer the listing of its common stock to the Nasdaq Capital Market, provided that it satisfies the Nasdaq Capital Market’s continued listing requirement for the market value of publicly held shares and all other initial listing standards, with the exception of its bid price requirement, and provides written notice to the Staff of its intention to cure the deficiency during the additional compliance period.